Liquid chromatography–mass spectrometric assay of androstenediol in prostatic tissue: Influence of androgen deprivation therapy on its level

Abstract

Androstenediol (Adiol, androst-5-ene-3β,17β-diol) is suspected of being an endogenous proliferation agent of prostate cancer (PCa) even after androgen deprivation therapy (ADT). A liquid chromatography–electron capture atmospheric pressure chemical ionization–mass spectrometric (LC–ECAPCI–MS) method for the determination of Adiol in prostatic tissue was developed and validated for evaluating the influence of ADT on the prostatic Adiol level. After derivatization of Adiol with 4-nitrobenzoyl chloride, the detection response of the derivative was increased 150 times more than that of intact Adiol. The LC–MS method was specific and reliable for the measurement of a trace amount of Adiol in 30 mg of tissue. The clinical study using the developed method showed that the prostatic Adiol level was not changed by ADT. That is, the prostatic Adiol levels of PCa patients with ADT ( n = 12), benign prostate hypertrophy patients without ADT ( n = 8) and bladder cancer patients (without prostatic disease) ( n = 6) were 0.83 ± 0.28, 0.62 ± 0.31 and 0.71 ± 0.28 ng g −1 tissue, respectively, and there was no significant difference between these groups.